IL160755A0 - Urea compounds active as vanilloid receptor antagonists for the treatment of pain - Google Patents

Urea compounds active as vanilloid receptor antagonists for the treatment of pain

Info

Publication number
IL160755A0
IL160755A0 IL16075502A IL16075502A IL160755A0 IL 160755 A0 IL160755 A0 IL 160755A0 IL 16075502 A IL16075502 A IL 16075502A IL 16075502 A IL16075502 A IL 16075502A IL 160755 A0 IL160755 A0 IL 160755A0
Authority
IL
Israel
Prior art keywords
pain
treatment
receptor antagonists
urea compounds
vanilloid receptor
Prior art date
Application number
IL16075502A
Other languages
English (en)
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0122156A external-priority patent/GB0122156D0/en
Priority claimed from GB0130547A external-priority patent/GB0130547D0/en
Priority claimed from GB0130503A external-priority patent/GB0130503D0/en
Priority claimed from GB0130505A external-priority patent/GB0130505D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of IL160755A0 publication Critical patent/IL160755A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
IL16075502A 2001-09-13 2002-09-13 Urea compounds active as vanilloid receptor antagonists for the treatment of pain IL160755A0 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0122156A GB0122156D0 (en) 2001-09-13 2001-09-13 Novel compounds
GB0130547A GB0130547D0 (en) 2001-12-20 2001-12-20 Novel compounds
GB0130503A GB0130503D0 (en) 2001-12-20 2001-12-20 Novel compounds
GB0130505A GB0130505D0 (en) 2001-12-20 2001-12-20 Novel compounds
PCT/GB2002/004206 WO2003022809A2 (en) 2001-09-13 2002-09-13 Urea-compounds active as vanilloid receptor antagonists for the treatment of pain

Publications (1)

Publication Number Publication Date
IL160755A0 true IL160755A0 (en) 2004-08-31

Family

ID=27447989

Family Applications (2)

Application Number Title Priority Date Filing Date
IL16075502A IL160755A0 (en) 2001-09-13 2002-09-13 Urea compounds active as vanilloid receptor antagonists for the treatment of pain
IL160755A IL160755A (en) 2001-09-13 2004-03-04 N - (2 - bromophenyl) - n' [((r) - 1 - (5 - trifluoromethyl - 2 - pyridyl) pyrrolidin - 3 - yl)] urea, pharmaceutical compositions comprising it and process for its preparation

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL160755A IL160755A (en) 2001-09-13 2004-03-04 N - (2 - bromophenyl) - n' [((r) - 1 - (5 - trifluoromethyl - 2 - pyridyl) pyrrolidin - 3 - yl)] urea, pharmaceutical compositions comprising it and process for its preparation

Country Status (32)

Country Link
US (1) US8063078B2 (sl)
EP (3) EP2036902A3 (sl)
JP (2) JP4463552B2 (sl)
KR (3) KR20100082390A (sl)
CN (1) CN1247568C (sl)
AP (1) AP1818A (sl)
AR (1) AR038786A1 (sl)
AT (1) ATE420083T1 (sl)
AU (1) AU2002329397B2 (sl)
BR (1) BR0212468A (sl)
CA (1) CA2458632C (sl)
CY (1) CY1109449T1 (sl)
DE (1) DE60230773D1 (sl)
DK (1) DK1425277T3 (sl)
EA (1) EA007731B1 (sl)
ES (1) ES2316607T3 (sl)
HK (1) HK1066534A1 (sl)
HU (1) HUP0401923A3 (sl)
IL (2) IL160755A0 (sl)
MA (1) MA26216A1 (sl)
MX (1) MXPA04002379A (sl)
MY (1) MY138086A (sl)
NO (3) NO327009B1 (sl)
NZ (1) NZ531137A (sl)
OA (1) OA12659A (sl)
PE (1) PE20030417A1 (sl)
PL (1) PL213639B1 (sl)
PT (1) PT1425277E (sl)
SI (1) SI1425277T1 (sl)
TW (1) TWI283665B (sl)
UY (1) UY27446A1 (sl)
WO (1) WO2003022809A2 (sl)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI283665B (en) 2001-09-13 2007-07-11 Smithkline Beecham Plc Novel urea compound, pharmaceutical composition containing the same and its use
JP4583760B2 (ja) 2002-02-01 2010-11-17 ユーロ−セルティーク エス．エイ． 疼痛の治療に有用な治療薬
US7074805B2 (en) 2002-02-20 2006-07-11 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
ES2319886T3 (es) * 2002-02-20 2009-05-14 Abbott Laboratories Compuestos azabiciclicos condensados que inhiben el sutipo 1 del receptor valinoide (vr1).
US6974818B2 (en) 2002-03-01 2005-12-13 Euro-Celtique S.A. 1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful for treating pain
WO2004002983A2 (en) 2002-06-28 2004-01-08 Euro-Celtique, S.A. Therapeutic piperazine derivatives useful for treating pain
US7262194B2 (en) 2002-07-26 2007-08-28 Euro-Celtique S.A. Therapeutic agents useful for treating pain
GB0221157D0 (en) * 2002-09-12 2002-10-23 Glaxo Group Ltd Novel treatment
WO2004024710A1 (en) * 2002-09-13 2004-03-25 Glaxo Group Limited Urea compounds active as vanilloid receptor antagonists for the treatment of pain
US7157462B2 (en) 2002-09-24 2007-01-02 Euro-Celtique S.A. Therapeutic agents useful for treating pain
EP1569896B1 (en) 2002-12-06 2007-08-15 Bayer HealthCare AG Tetrahydro-naphthalene derivatives
GB0229808D0 (en) * 2002-12-20 2003-01-29 Glaxo Group Ltd Novel compositions
US6933311B2 (en) * 2003-02-11 2005-08-23 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
ES2330107T3 (es) * 2003-03-06 2009-12-04 Glaxo Group Limited Derivados de urea heterociclicos para el tratamiento del dolor.
WO2004078744A2 (en) * 2003-03-07 2004-09-16 Glaxo Group Limited Urea derivatives and their use as vanilloid receptor antagonists in the treatment of pain
GB0305426D0 (en) 2003-03-08 2003-04-16 Glaxo Group Ltd Novel compounds
SE0301446D0 (sv) 2003-05-16 2003-05-16 Astrazeneca Ab New Compounds
WO2004103954A1 (ja) 2003-05-20 2004-12-02 Ajinomoto Co., Inc. アミド誘導体
EP1493438A1 (en) * 2003-07-03 2005-01-05 Bayer HealthCare AG Vanilloid receptor (VR) inhibitors for treatment of Human Immunodeficiency Virus (HIV)-mediated pain states
GB0319151D0 (en) * 2003-08-14 2003-09-17 Glaxo Group Ltd Novel compounds
GB0319150D0 (en) 2003-08-14 2003-09-17 Glaxo Group Ltd Novel compounds
EP2048132B1 (en) 2003-10-01 2011-04-13 Xention Limited Tetrahydro-naphthalene and urea derivatives
JP4935073B2 (ja) 2003-10-14 2012-05-23 味の素株式会社 エーテル誘導体
WO2005040100A1 (en) * 2003-10-15 2005-05-06 Bayer Healthcare Ag Tetrahydro-naphthalene and urea derivatives
US7683076B2 (en) 2003-11-08 2010-03-23 Bayer Schering Pharma Aktiengesellschaft Tetrahydro-quinolinylurea derivatives
WO2005095327A1 (ja) 2004-03-31 2005-10-13 Ajinomoto Co., Inc. アニリン誘導体
US7687665B2 (en) 2004-06-24 2010-03-30 Incyte Corporation 2-methylprop anamides and their use as pharmaceuticals
JP2008508190A (ja) 2004-07-19 2008-03-21 ノボ ノルディスク アクティーゼルスカブ 肥満または肥満に関連する疾患および障害の治療におけるカプサイシン受容体の活性の阻害
KR20060087386A (ko) 2005-01-28 2006-08-02 주식회사 대웅제약 신규 벤조이미다졸 유도체 및 이를 함유하는 약제학적조성물
WO2006098554A1 (en) * 2005-03-16 2006-09-21 Amorepacific Corporation Novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and a pharmaceutical composition containing the same
WO2007046867A2 (en) * 2005-05-19 2007-04-26 Xenon Pharmaceuticals Inc. Piperidine derivatives and their uses as therapeutic agents
UY30048A1 (es) 2005-12-23 2007-07-31 Astrazeneca Ab Derivados sustituidos de la n,2-(1h-benzimidazol-1-il) acetamida, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones
EP1889830A1 (en) * 2006-07-10 2008-02-20 Pharmeste S.r.l. Biarylcarboxyarylamides as vanilloid-1 receptor modulators
CA2658925C (en) * 2006-07-27 2015-07-14 Amorepacific Corporation Novel sulfonylamino acrylamide derivatives, isomer thereof,or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
EP1882687A1 (en) * 2006-07-27 2008-01-30 Amorepacific Corporation Heterocyclic compounds useful as vanilloid receptor antagonists and pharmaceutical compositions containing the same
TWI433839B (zh) 2006-08-11 2014-04-11 Neomed Inst 新穎的苯并咪唑衍生物290
WO2008024945A1 (en) 2006-08-25 2008-02-28 Abbott Laboratories Indazole derivatives that inhibit trpv1 and uses thereof
MX2009006730A (es) 2006-12-20 2009-06-30 Abbott Lab Derivados de n-(5, 6, 7, 8-tetrahidronaftalen-1-il) urea y compuestos relacionados como antagonistas de receptor vaniloide trpv1 par el tratamiento de dolor.
US8232411B2 (en) 2008-03-20 2012-07-31 Abbott Laboratories Methods for making central nervous system agents that are TRPV1 antagonists
JP5372138B2 (ja) 2008-04-18 2013-12-18 テウン ファーマシューティカル カンパニー，リミテッド 新規ベンゾオキサジンベンズイミダゾール誘導体、これを含む薬学組成物およびこの用途
ES2433008T3 (es) * 2008-05-07 2013-12-05 Dainippon Sumitomo Pharma Co., Ltd. Derivado de éster de ácido amino-1-carboxílico cíclico y composición farmacéutica que contiene el mismo
WO2010026128A1 (en) * 2008-09-02 2010-03-11 Glaxo Group Limited N-(3-methyl-5-isoquinolinyl)-n'-((3r)-1-[5-(trifluoromethyl)-2-pyridinyl]-3-pyrrolidinyl) urea for the treatment of rhinitis
EP2340023A1 (en) * 2008-09-02 2011-07-06 Glaxo Group Limited The trpvl antagonist sb-705498 for treating rhinitis
JP2013028536A (ja) * 2009-11-11 2013-02-07 Dainippon Sumitomo Pharma Co Ltd 環状アミン−１−カルボン酸エステル誘導体およびそれを含有する医薬組成物
WO2012045729A1 (en) 2010-10-05 2012-04-12 Glaxo Group Limited Imidazo [1, 2 -a] pyridine and pyrazolo [1, 5 -a] pyridine derivatives as trpv1 antagonists
KR101293384B1 (ko) 2010-10-13 2013-08-05 주식회사 대웅제약 신규 피리딜 벤조옥사진 유도체, 이를 포함하는 약학 조성물 및 이의 용도
WO2012072512A1 (en) 2010-11-29 2012-06-07 Glaxo Group Limited N-cyclobutyl-imidazopyridine or -pyrazolopyridine carboxamides as trpv1 antagonists
GB201101517D0 (en) * 2011-01-28 2011-03-16 Proximagen Ltd Receptor antagonists
US8754101B2 (en) 2011-04-11 2014-06-17 Glaxo Group Limited N-cyclobutyl-imidazopyridine-methylamine as TRPV1 antagonists
DE102022104759A1 (de) 2022-02-28 2023-08-31 SCi Kontor GmbH Co-Kristall-Screening Verfahren, insbesondere zur Herstellung von Co-Kristallen

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3424761A (en) * 1966-03-07 1969-01-28 Robins Co Inc A H 3-ureidopyrrolidines
US3424760A (en) * 1966-03-07 1969-01-28 Robins Co Inc A H 3-ureidopyrrolidines
GB1460389A (en) * 1974-07-25 1977-01-06 Pfizer Ltd 4-substituted quinazoline cardiac stimulants
DE68918991T2 (de) 1988-06-17 1995-04-27 Procter & Gamble Anwendung von Vanillin-Derivaten zur Herstellung eines Arzneimittels zur Behandlung von Herpes simplex-Infektion.
HU206082B (en) 1988-12-23 1992-08-28 Sandoz Ag Process for producing capsaicin derivatives and pharmaceutical compositions comprising such compounds
CA2017383A1 (en) 1989-06-08 1990-12-08 Raymond R. Martodam Use of vanilloids for the treatment of respiratory diseases or disorders
AU9079491A (en) 1990-11-27 1992-06-25 Procter & Gamble Company, The Combinations of vanilloid compounds and phosphonate antiviral compounds for treatment of herpes infections
US5149704A (en) * 1991-05-03 1992-09-22 Abbott Laboratories Platelet activating antagonists
CA2197364A1 (en) * 1996-02-15 1997-08-16 Toshikazu Suzuki Phenol compound and process for preparing the same
WO1999000128A1 (en) * 1997-06-26 1999-01-07 Eli Lilly And Company Antithrombotic agents
JP2002512633A (ja) 1997-06-26 2002-04-23 イーライ・リリー・アンド・カンパニー 抗血栓剤
JP2000080085A (ja) * 1997-09-01 2000-03-21 Kyorin Pharmaceut Co Ltd ６，７−非対称ジ置換キノキサリンカルボン酸誘導体とその付加塩及びそれらの製造方法
MXPA01008403A (es) 1999-02-22 2003-06-06 Pacific Corp Analogos vainillinoides que contienen farmacoforos resiniferatoxinicos como potentes agonistas del receptor para vainillinoides y analgesicos, composiciones y usos de estos.
RU2242474C2 (ru) 1999-03-12 2004-12-20 Бёрингер Ингельхайм Фармасьютиклз, Инк. Соединения, пригодные в качестве противовоспалительных агентов
US6608227B1 (en) * 1999-10-15 2003-08-19 Bristol-Myers Squibb Pharma Benzylcycloalkyl amines as modulators of chemokine receptor activity
NZ523526A (en) 2000-07-20 2004-10-29 Neurogen Corp Diaryl piperazines as capsaicin receptor ligands
WO2002016318A1 (en) 2000-08-21 2002-02-28 Pacific Corporation Novel thiourea derivatives and the pharmaceutical compositions containing the same
WO2002016317A1 (en) 2000-08-21 2002-02-28 Pacific Corporation Novel thiocarbamic acid derivatives and the pharmaceutical compositions containing the same
ATE328868T1 (de) 2000-08-21 2006-06-15 Pacific Corp Neue (thio)harnstoffverbindungen und arzneimittelkompositionen, die diese enthalten
JP2002080073A (ja) 2000-09-07 2002-03-19 Kyokuto Kobunshi Kk 電子レンジ用自動開孔袋
JP2002088073A (ja) * 2000-09-08 2002-03-27 Yamanouchi Pharmaceut Co Ltd 抗アンドロゲン剤
GB0110901D0 (en) * 2001-05-02 2001-06-27 Smithkline Beecham Plc Novel Compounds
TWI283665B (en) 2001-09-13 2007-07-11 Smithkline Beecham Plc Novel urea compound, pharmaceutical composition containing the same and its use
BR0312204A (pt) * 2002-06-27 2005-04-26 Schering Ag Antagonista de receptor ccr5 de quinolina substituìda
WO2004024710A1 (en) * 2002-09-13 2004-03-25 Glaxo Group Limited Urea compounds active as vanilloid receptor antagonists for the treatment of pain
GB0229808D0 (en) 2002-12-20 2003-01-29 Glaxo Group Ltd Novel compositions
EP1740557A1 (en) 2004-04-20 2007-01-10 Bayer HealthCare AG Urea derivatives as antagonists of the vanilloid receptor (vr1)

Also Published As

Publication number Publication date
ES2316607T3 (es) 2009-04-16
AP2004002982A0 (en) 2004-03-31
JP2005504074A (ja) 2005-02-10
MXPA04002379A (es) 2004-05-31
PL369026A1 (en) 2005-04-18
TWI283665B (en) 2007-07-11
NO20085077L (no) 2004-06-04
WO2003022809A2 (en) 2003-03-20
EP2036902A3 (en) 2009-05-06
ATE420083T1 (de) 2009-01-15
CA2458632C (en) 2011-08-23
WO2003022809A3 (en) 2003-07-17
AP1818A (en) 2008-01-07
DK1425277T3 (da) 2009-03-16
KR101063679B1 (ko) 2011-09-07
EP2036902A2 (en) 2009-03-18
EP1425277B1 (en) 2009-01-07
EP1425277A2 (en) 2004-06-09
HUP0401923A2 (hu) 2005-01-28
EA007731B1 (ru) 2006-12-29
OA12659A (en) 2006-06-19
CA2458632A1 (en) 2003-03-20
PT1425277E (pt) 2009-03-05
US20090163506A1 (en) 2009-06-25
EP2298757A3 (en) 2011-12-28
HK1066534A1 (en) 2005-03-24
EA200400432A1 (ru) 2004-12-30
EP2298757A2 (en) 2011-03-23
MY138086A (en) 2009-04-30
NO327009B1 (no) 2009-04-06
UY27446A1 (es) 2003-04-30
CN1553905A (zh) 2004-12-08
BR0212468A (pt) 2004-10-19
KR20040041610A (ko) 2004-05-17
NZ531137A (en) 2006-08-31
CN1247568C (zh) 2006-03-29
EP1425277B8 (en) 2009-04-01
DE60230773D1 (de) 2009-02-26
AU2002329397B2 (en) 2006-04-27
JP4463552B2 (ja) 2010-05-19
NO20085078L (no) 2004-06-04
US8063078B2 (en) 2011-11-22
AR038786A1 (es) 2005-01-26
CY1109449T1 (el) 2014-08-13
SI1425277T1 (sl) 2009-04-30
KR20090026369A (ko) 2009-03-12
MA26216A1 (fr) 2004-07-01
KR100955967B1 (ko) 2010-05-04
JP2010100632A (ja) 2010-05-06
IL160755A (en) 2009-09-01
KR20100082390A (ko) 2010-07-16
HUP0401923A3 (en) 2012-09-28
NO20041003L (no) 2004-06-04
PE20030417A1 (es) 2003-08-06
PL213639B1 (pl) 2013-04-30

Similar Documents

Publication Publication Date Title
IL160755A0 (en) Urea compounds active as vanilloid receptor antagonists for the treatment of pain
AU2003270199A1 (en) Urea compounds active as vanilloid receptor antagonists for the treatment of pain
NO20034122D0 (no) Sammensmeltede pyridinderivater for anvendelse som vanilloidreseptorantagonister for behandling av smerte
HK1047580B (zh) 在糖尿病治療中作為糖皮質激素受體對抗劑的二苯並吡喃
WO2002072536A8 (en) Urea derivatives having vanilloid receptor (vr1) antagonist activity
IL160884A0 (en) Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
NO20042208L (no) Vaginalt administrerte anti-dysrytmiske midler for behandling av bekkensmerter
NO20020574D0 (no) Substituerte 1,5-dihydropyrrol-2-onderivater som er virksomme som NMDA-reseptorantagonister for behandlingen av smertetilstanden
HUP0202253A3 (en) Selective iglur5 receptor antagonists for the treatment of migraine
AU2003290059A8 (en) Use of cd137 antagonists for the treatment of tumors
IL157145A0 (en) Use of dc23 antagonists for the treatment of neoplastic disorders
IL158829A0 (en) Exothermic formulations for the treatment of ectoparasites
IL157593A0 (en) Carbamate compounds for use in the treatment of pain
EP1399175A4 (en) THERAPEUTIC USE OF RANK ANTAGONISTS
AU2003264297A1 (en) Use of vanilloid receptor antagonists for the treatment of pain
EP1208101A4 (en) VITRONECTIN RECEPTOR ANTAGONISTS USEFUL FOR THE TREATMENT OF VASCULAR ACCIDENTS
GB9904252D0 (en) Composition for the treatment of pain
HUP0300313A3 (en) Compound, pharmaceutical composition containing it and its use for the treatment of pain
EP1451308A4 (en) THERAPEUTIC USE OF AZIRIDINO COMPOUNDS
AU2002316237A1 (en) Use of the parathroid hormone-2 (pth2) receptor to screen for agents to treat pain
AU2003245995A8 (en) Use of gaba-c receptor antagonists for the treatment of myopia
EP1377289A4 (en) HETEROCYCLIC COMPOUNDS WITH THERAPEUTIC USE
AU2002326276A1 (en) N-type calcium channel antagonists for the treatment of pain
AU2002327697A1 (en) Compounds for the treatment of pain
GB9918000D0 (en) Compositions for the treatment of pain